BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025
NEW YORK, May 7, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2025, and provide a corporate update, at 8:30 a.m. Eastern Time on Thursday, May 15, 2025.
BrainStorm Logo
BrainStorm's President & Chief Executive Officer, Chaim Lebovits, will present a corporate update to be followed by Q&A. Joining Mr. Lebovits to answer investment community questions will be Bob Dagher, M.D., Chief Medical Officer, and Alla Patlis, CPA, MBA, Interim Chief Financial Officer.
Participants are encouraged to submit their questions in advance of the call by sending them to: q@brainstorm-cell.com. Questions should be submitted by 5:00 p.m. Eastern Time on Monday, May 12, 2025.
Investors may access the conference call by dialing the following numbers:
Participant Numbers:
Toll Free
888-506-0062
International
973-528-0011
Participant Access Code
621608
Webcast
https://www.webcaster4.com/Webcast/Page/2354/52457
The replay of the conference call can be accessed by dialing the numbers below and will be available for 14 days.
Replay Numbers:
Toll Free
877-481-4010
International
919-882-2331
Reply Passcode
52457
About Brainstorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection.
NurOwn® is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a confirmatory Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the "Floor Effect" — a critical challenge in measuring clinical outcomes in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging area of regenerative medicine.To learn more, visit www.brainstorm-cell.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Why Braze, Inc. (BRZE) Crashed On Friday
We recently published a list of . In this article, we are going to take a look at where Braze, Inc. (NASDAQ:BRZE) stands against other Friday's worst-performing stocks. Braze Inc. dropped its share prices by 17.65 percent on Friday to finish at $29.73 apiece as investors soured on its dismal earnings performance in the first quarter of fiscal year 2026. In a statement, Braze, Inc. (NASDAQ:BRZE) said attributable net loss was unchanged at $35 million, despite revenues increasing by 20 percent to $162 million from $135 million, driven primarily by new customers, upsells, and renewals. A web developer hunched over their laptop coding a customer engagement platform. For the second quarter of the year, Braze, Inc. (NASDAQ:BRZE) is targeting to hit $171 million to $172 million in revenues, with a net income ranging from $2.5 million to $3.5 million. The full-year period alone is expected to rake in between $702 million and $706 million in revenues, and a net income of $17 million to $21 million. The company also welcomed Ed McDonnell as its new chief revenue officer. 'McDonnell has a strong track record of delivering results at high-growth public SaaS businesses, and we believe his extensive background in Software and Customer Engagement will further solidify Braze as the leading customer engagement platform and accelerate growth in the coming years,' said Braze, Inc. (NASDAQ:BRZE) CEO Bill Magnuson. Overall, BRZE ranks 3rd on our list of Friday's worst-performing stocks. While we acknowledge the potential of BRZE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Why DocuSign, Inc. (DOCU) Crashed On Friday
We recently published a list of . In this article, we are going to take a look at where DocuSign, Inc. (NASDAQ:DOCU) stands against other Friday's worst-performing stocks. DocuSign dropped its share prices by 18.97 percent on Friday to end at $75.28 apiece after slashing its full-year billing outlook amidst its shift to an artificial intelligence model. For the full year period, DocuSign, Inc. (NASDAQ:DOCU) now expects billings to settle in the range of $3.285 billion to $3.339 billion, down from its previous outlook of $3.30 billion to $3.354 billion. A software engineer in front of a computer screen, typing code to build the company's electronic signature software. According to DocuSign, Inc. (NASDAQ:DOCU) CEO Allan Thygesen, the decline in billings this year was expected due to 'foundational go-to-market changes' following the adoption of Intelligent Agreement Management, an AI-driven agreement platform. However, Thygesen said that 'the impact happened sooner than anticipated,' causing the drop in early renewals during the first quarter period, and negatively impacting billings growth. In the first quarter of the year, DocuSign, Inc. (NASDAQ:DOCU) achieved a 118-percent jump in net income to $72 million from $33 million in the same period last year. Revenues increased by 7.6 percent to $763 million from $709 million year-on-year. Overall, DOCU ranks 2nd on our list of Friday's worst-performing stocks. While we acknowledge the potential of DOCU as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
an hour ago
- Yahoo
Why Lululemon Athletica Inc. (LULU) Crashed On Friday
We recently published a list of . In this article, we are going to take a look at where Lululemon Athletica Inc. (NASDAQ:LULU) stands against other Friday's worst-performing stocks. Lululemon fell by 19.8 percent on Friday to finish at $265.27 apiece following a disappointing earnings performance and outlook guidance for the rest of the year. In its financial statement, Lululemon Athletica Inc. (NASDAQ:LULU) said net income in the first quarter of the year dipped by 2 percent to $314 million from $321 million in the same period last year. Net revenues, on the other hand, grew by 7 percent to $2.37 billion from $2.2 billion year-on-year. A store employee in an athletic apparel store restocking merchandise. For the second quarter of the year, Lululemon Athletica Inc. (NASDAQ:LULU) expects net revenue to be in the range of $2.535 billion to $2.56 billion, representing growth of 7 percent to 8 percent. For the full-year period, it said targets net revenue to be in the range of $11.15 billion to $11.3 billion, representing growth of 5 to 7 percent. Following the guidance, JPMorgan and UBS both reduced their price targets for the company to $303 and $290, respectively, from $389 and $330 previously. Overall, LULU ranks 1st on our list of Friday's worst-performing stocks. While we acknowledge the potential of LULU as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
